ReviewImmunologic research2014
Prostate cancer vaccines in combination with additional treatment modalities.
Review in Immunologic research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Recent advances and future perspectives in the therapeutics of prostate cancer.Experimental hematology & oncology · 2023Article
- Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.Biomedicines · 2022Review
- Natriuretic Peptides: The Case of Prostate Cancer.Molecules (Basel, Switzerland) · 2017Review
- Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.Frontiers in oncology · 2017Review
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
- Article
- Immune Infiltration and Prostate Cancer.Frontiers in oncology · 2015Review
- The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study.Human vaccines & immunotherapeutics · 2015Article
- Translational research in oncology--10 years of progress and future prospects.Nature reviews. Clinical oncology · 2014Review
- From bench to bedside: immunotherapy for prostate cancer.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has been investigated in both preclinical studies and clinical trials as a new therapy for prostate cancer. Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase. The vaccines have long been studied as monotherapy for the cancer, but increasingly more trials have been initiated in combination with other modalities. These include radiation, chemotherapy, and androgen deprivation therapy. This review describes and discusses the various combinations of vaccine immunotherapies.
Indexed as
Identifiers
24838261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.